As a result, Bavarian Nordic has completed the direct placement to Johnson & Johnson Innovation - JJDC
Inc, consisting of 512,102 new shares of nominal value DKK10 each, corresponding to approximately 1.63% of the company's existing share capital, issued at a subscription price of DKK 405.1578 per new share and raising gross proceeds to Bavarian Nordic of DKK207.5m.
Johnson & Johnson Innovation -- JJDC
is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in the medical device, diagnostic, pharmaceutical, and consumer health areas.
Vale joined JJDC
in 1992, and in 1997 moved to California to establish the Silicon Valley office.
NORDIC BUSINESS REPORT-August 10, 2017-Bavarian Nordic declares subscription price and number of shares to be issued to JJDC
under license and collaboration agreement
was established by Index Ventures as an asset centric company, a model advanced by Index, via a fund launched in 2012 in which Johnson and Johnson Innovation JJDC
Johnson & Johnson Development Corporation (JJDC
) is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in the medical device, diagnostic, pharmaceutical, and consumer health areas.
Johnson and Johnson Innovation JJDC
, Inc., Novartis Institutes for BioMedical Research, and Osage University Partners also participated in the round along with Vor Co-founder PureTech Health.
Bavarian Nordic A/S (CPH:BAVA) (OTC:BVNRY) announced on Tuesday the receipt of notification from Johnson & Johnson Innovation - JJDC
) to leverage these funds along with those from additional external investors.
), J&J's venture capital arm, are co-located at the Boston Innovation Center to identify opportunities and invest in them.